ERBB2 and breast cancer: In a preclinical study, co-expression of HER2 and IGF1R in breast cancer cells resulted in loss of sensitivity to trastuzumab treatment, whereas blocking ligand activation of IGF1R restored trastuzumab-related growth inhibition [25].